This article is more than 5 years old. Information may no longer be current.

Early AMD detection with preferential hyperacuity perimetry may improve outcomes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

KOLOA, Hawaii — Using preferential hyperacuity perimetry may lead to earlier diagnosis of AMD compared with current measurements. Earlier diagnosis could result in earlier treatment and improved visual outcomes, according to a speaker here.

Allen C. Ho, MD, OSN Retina/Vitreous Section Member, said at the Retina 2007 meeting that although significant advancements in treatment therapies for age-related macular degeneration have been made, "without early detection of the progression to CNV, even the best therapy will result in significantly impaired vision."

"Earlier detection is needed to take advantage of the new therapies. CNV often grows rapidly, so monitoring patients more frequently may result in better visual outcomes," he said.

Dr. Ho cited a study that showed eight out of 10 patients who develop CNV would be diagnosed earlier with PHP than they would with current diagnostics.

"Monitoring patients with hyperacuity perimetry may result in earlier detection of wet AMD and may permit better visual outcomes," he said. "I think that's a reasonable assumption."

With PHP, Dr. Ho said it is necessary to change patients' examination schedule in order to catch the early progression of CNV.

"For patients diagnosed with intermediate stage dry AMD, schedule a PHP test every 3 months and look for progression to CNV," he said.

In his presentation, Dr. Ho discussed studies with the PreView PHP, which was distributed by Carl Zeiss Meditec. The second generation device, called Foresee PHP, is manufactured by Notal Vision and distributed by MSS.